Home
CISMAC
New Study

Launch of BCG study in Uganda

In 2015, it was estimated that 1 of 10 Ugandan children do not live beyond their fifth birthday and in total, 39,000 new-born die every year.

It is against this background that Dr Victoria Nankabirwa, a senior lecturer in the Department of Epidemiology and Biostatistics, School of Public Health and also a senior researcher at the University of Bergen, together with other researchers decided to conduct a study on other health benefits of the BCG vaccine. This vaccine is given to new born babies in the first few hours of their life to boost their immunity against tuberculosis.

The Ugandan newspaper Daily Monitor was present at the launch of the study, in August 2016. 

Read the full story in Daily Monitor

More about the study: 

Delayed BCG vaccination in HIV infants in Uganda

It is possible that BCG vaccination at birth can protect infants against several serious infections, not only against tuberculosis. Randomised control trials are required to inform the development of strategies for BCG vaccination by measuring whether deferring vaccination from birth to 14 weeks of age changes immune responses to BCG and the risk of serious illness during the first two years of life. The first draft Study Protocol for this study is being completed.

Project management team (PMT) leaders: Victoria Nankabirwa / Halvor Sommerfelt